Publication Name	World Journal of Clinical Oncology
Manuscript ID	9473
Country	Italy

Received	2014-02-13 14:50
Peer-Review Started	2014-02-13 20:07
First Decision by Editorial Office Director
Return for Revision	2014-04-10 22:58
Revised	2014-05-12 15:57
Publication Fee Transferred
Second Decision by Editor	2014-07-18 13:48
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-07-18 13:58
Articles in Press	2014-07-18 13:58
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-18 09:07
Publish the Manuscript Online	2014-12-11 14:23

ISSN	2218-4333 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions
Manuscript Source	Invited Manuscript
All Author List	Andrea Milani, Elena Geuna, Gloria Mittica and Giorgio Valabrega
Funding Agency and Grant Number
Corresponding Author	Giorgio Valabrega, MD, Institute for Cancer Research at Candiolo, University of Torino Medical School, FPO (Fondazione del Piemonte per l’Oncologia), SP 142, Km. 3.95, 10060 Candiolo, Italy. giorgio.valabrega@ircc.it
Key Words	Everolimus; Mammalian target of rapamycin; PI3K inhibitors; Estrogen receptor; Endocrine resistance
Core Tip	Endocrine therapy is the backbone therapy for HR-positive MBC patients. Unfortunately, resistance to endocrine agents invariably develops in the majority of patients. A deeper knowledge of the molecular mechanisms driving endocrine resistance boosted the development of strategies designed to effectively overcome resistance endocrine therapy. In particular, co-targeting of tyrosine kinase receptors pathway and intracellular signalling pathway such as PI3K-Akt-mTor, emerged as particular promising strategy. In the near future, development of new drugs with strong biological rationale and a more personalized selection of treatments could further improve the outcome of HR-positive MBC.
Publish Date	2014-12-11 14:23
Citation	Milani A, Geuna E, Mittica G, Valabrega G. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. World J Clin Oncol 2014; 5(5): 990-1001
URL	http://www.wjgnet.com/2218-4333/full/v5/i5/990.htm
DOI	http://dx.doi.org/10.5306/wjco.v5.i5.990

Full Article (PDF)	WJCO-5-990.pdf
Full Article (Word)	WJCO-5-990.doc
Manuscript File	9473-Review.docx
Answering Reviewers	9473-Answering reviewers.pdf
Copyright License Agreement	9473-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	9473-Language certificate.pdf
Peer-review Report	9473-Peer review(s).pdf
Scientific Misconduct Check	9473-CrossCheck.jpg
Scientific Editor Work List	9473-Scientific editor work list.pdf